Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancerYoshikazu Johmura, Makoto Nakanishi, Kiyoshi Yamaguchi et al.|Journal of Clinical Investigation|2018Cited by 78
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinomaSaki Nakagawa, Takanori Ishida, Minoru Miyashita et al.|Breast Cancer Research and Treatment|2024Cited by 2
Trastuzumab Deruxtecan in a Patient with Breast Cancer on Hemodialysis: a Case ReportMarii Suehiro, Tsuneaki Tanaka, Yasuyuki Kojima et al.|Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)|2022Cited by 0